Literature DB >> 25536292

Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice.

Katherine Perschbacher1, John A Smestad, Justin P Peters, Miranda M Standiford, Aleksandar Denic, Bharath Wootla, Arthur E Warrington, Moses Rodriguez, L James Maher.   

Abstract

DNA aptamer oligonucleotides and their protein conjugates show promise as therapeutics in animal models of diseases such as multiple sclerosis. These molecules are large and highly charged, raising questions about their biodistribution and pharmacokinetics in mammals. Here we exploit the power of quantitative polymerase chain reaction to accurately quantitate the tissue distribution of 40-nucleotide DNA aptamers and their streptavidin conjugates after intraperitoneal injection in mice. We show remarkably rapid distribution to peripheral tissues including the central nervous system. Modeling of tissue distribution data reveals the importance of DNA aptamer sequence, 3' modification, and protein conjugation in enhancing tissue exposure. These data help to interpret the previously observed effectiveness of aptamer conjugates, as opposed to free aptamers, in stimulating central nervous system remyelination in a mouse model of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25536292      PMCID: PMC4296750          DOI: 10.1089/nat.2014.0515

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  34 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.

Authors:  P M Friden; L R Walus; G F Musso; M A Taylor; B Malfroy; R M Starzyk
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 3.  Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy.

Authors:  Michael Famulok; Jörg S Hartig; Günter Mayer
Journal:  Chem Rev       Date:  2007-08-23       Impact factor: 60.622

4.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

5.  The derivation of the gamma-variate relationship for tracer dilution curves.

Authors:  R Davenport
Journal:  J Nucl Med       Date:  1983-10       Impact factor: 10.057

6.  Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis.

Authors:  S F Hunter; D J Miller; M Rodriguez
Journal:  J Neurol Sci       Date:  1997-09-10       Impact factor: 3.181

7.  Pharmacokinetics and biodistribution of novel aptamer compositions.

Authors:  Judith M Healy; Scott D Lewis; Markus Kurz; Ryan M Boomer; Kristin M Thompson; Charles Wilson; Thomas G McCauley
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

8.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

Authors:  S Agrawal; J Temsamani; J Y Tang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

9.  Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats.

Authors:  L Reyderman; S Stavchansky
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

10.  Whole-body scanning PCR; a highly sensitive method to study the biodistribution of mRNAs, noncoding RNAs and therapeutic oligonucleotides.

Authors:  Julien A Boos; David W Kirk; Mari-Luz Piccolotto; Werner Zuercher; Sandro Gfeller; Philippe Neuner; Andre Dattler; William L Wishart; Fabian Von Arx; Michael Beverly; Jesper Christensen; Karine Litherland; Esther van de Kerkhof; Pieter J Swart; Thomas Faller; Armin Beyerbach; David Morrissey; Juerg Hunziker; Iwan Beuvink
Journal:  Nucleic Acids Res       Date:  2013-06-13       Impact factor: 16.971

View more
  11 in total

Review 1.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

Review 2.  Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression.

Authors:  Hussein Baharlooi; Amir Hossein Mansourabadi; Moein Minbashi Moeini; Leila Mohamed Khosroshahi; Maryam Azimi
Journal:  Cell Mol Neurobiol       Date:  2021-10-25       Impact factor: 4.231

3.  Efficient functional neutralization of lethal peptide toxins in vivo by oligonucleotides.

Authors:  Tarek Mohamed Abd El-Aziz; Corinne Ravelet; Jordi Molgo; Emmanuelle Fiore; Simon Pale; Muriel Amar; Sawsan Al-Khoury; Jérôme Dejeu; Mahmoud Fadl; Michel Ronjat; Germain Sotoing Taiwe; Denis Servent; Eric Peyrin; Michel De Waard
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

4.  An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis.

Authors:  Robin M Heider; John A Smestad; Hernan Nicolas Lemus; Brandon Wilbanks; Arthur E Warrington; Justin P Peters; Moses Rodriguez; L James Maher
Journal:  Mol Ther Methods Clin Dev       Date:  2018-03-21       Impact factor: 6.698

5.  Optimization of a 40-mer Antimyelin DNA Aptamer Identifies a 20-mer with Enhanced Properties for Potential Multiple Sclerosis Therapy.

Authors:  Brandon Wilbanks; John Smestad; Robin M Heider; Arthur E Warrington; Moses Rodriguez; L James Maher
Journal:  Nucleic Acid Ther       Date:  2019-03-11       Impact factor: 5.486

6.  A chemically unmodified agonistic DNA with growth factor functionality for in vivo therapeutic application.

Authors:  Ryosuke Ueki; Satoshi Uchida; Naoto Kanda; Naoki Yamada; Ayaka Ueki; Momoko Akiyama; Kazuko Toh; Horacio Cabral; Shinsuke Sando
Journal:  Sci Adv       Date:  2020-04-01       Impact factor: 14.136

7.  Remyelination-Promoting DNA Aptamer Conjugate Myaptavin-3064 Binds to Adult Oligodendrocytes In Vitro.

Authors:  Mahboubeh Fereidan-Esfahani; Wei Ying Yue; Brandon Wilbanks; Aaron J Johnson; Arthur E Warrington; Charles L Howe; Moses Rodriguez; Louis J Maher
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-19

8.  Bioanalysis in the Age of New Drug Modalities.

Authors:  Jing Shi; Xuesong Chen; Jianbo Diao; Liying Jiang; Lan Li; Stephen Li; Wenzhong Liang; Xiaoying Jin; Yonghui Wang; Colton Wong; Xiaolong Tom Zhang; Francis L S Tse
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

9.  Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice.

Authors:  Luyao Wang; Yuanyuan Yu; Shuaijian Ni; Dijie Li; Jin Liu; Duoli Xie; Hang Yin Chu; Qing Ren; Chuanxin Zhong; Ning Zhang; Nanxi Li; Meiheng Sun; Zong-Kang Zhang; Zhenjian Zhuo; Huarui Zhang; Shu Zhang; Mei Li; Weibo Xia; Zhenlin Zhang; Lin Chen; Peng Shang; Xiaohua Pan; Aiping Lu; Bao-Ting Zhang; Ge Zhang
Journal:  Theranostics       Date:  2022-07-18       Impact factor: 11.600

10.  Application of aptamers in regenerative medicine.

Authors:  Zhaohui Luo; Shimin Chen; Jing Zhou; Chong Wang; Kai Li; Jia Liu; Yujin Tang; Liqiang Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.